<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02153398</url>
  </required_header>
  <id_info>
    <org_study_id>D961TC00002</org_study_id>
    <secondary_id>26-022</secondary_id>
    <nct_id>NCT02153398</nct_id>
  </id_info>
  <brief_title>A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases</brief_title>
  <official_title>An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and
      efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in
      Japanese paediatric patients aged 1 to 14 years old who either have a diagnosis of or are
      suspected to have gastric ulcer (GU), duodenal ulcer (DU), anastomotic ulcer (AU),
      non-erosive reflux esophagitis disease (NERD), reflux esophagitis (RE) or Zollinger-Ellison
      syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disappearance of Heartburn at Week 8 by Patient Diaries</measure>
    <time_frame>8 weeks</time_frame>
    <description>The disappearance of heartburn was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of heartburn were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disappearance of Epigastric Pain at Week 8 by Patient Diaries</measure>
    <time_frame>8 weeks</time_frame>
    <description>The disappearance of epigastric pain was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of epigastric pain were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disappearance of Upper Abdominal Discomfort at Week 8 by Patient Diaries</measure>
    <time_frame>8 weeks</time_frame>
    <description>The disappearance of upper abdominal discomfort was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of upper abdominal discomfort were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disappearance of Regurgitation at Week 8 by Patient Diaries</measure>
    <time_frame>8 weeks</time_frame>
    <description>The disappearance of regurgitation was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of regurgitation were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggravation of Heartburn at Week 8 by Patient Diaries</measure>
    <time_frame>8 weeks</time_frame>
    <description>The aggravation of heartburn was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of heartburn were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggravation of Epigastric Pain at Week 8 by Patient Diaries</measure>
    <time_frame>8 weeks</time_frame>
    <description>The aggravation of epigastric pain was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of epigastric pain were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggravation of Upper Abdominal Discomfort at Week 8 by Patient Diaries</measure>
    <time_frame>8 weeks</time_frame>
    <description>The aggravation of upper abdominal discomfort was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of upper abdominal discomfort were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggravation of Regurgitation at Week 8 by Patient Diaries</measure>
    <time_frame>8 weeks</time_frame>
    <description>The aggravation of regurgitation was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of regurgitation were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disappearance of Heartburn at Week 8 by Investigators</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators assessed the presence/absence and the intensity of heartburn at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of heartburn were defined as those who had a heartburn at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disappearance of Epigastric Pain at Week 8 by Investigators</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators assessed the presence/absence and the intensity of epigastric pain at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of epigastric pain were defined as those who had an epigastric pain at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disappearance of Upper Abdominal Discomfort at Week 8 by Investigators</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators assessed the presence/absence and the intensity of upper abdominal discomfort at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of upper abdominal discomfort were defined as those who had an upper abdominal discomfort at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disappearance of Regurgitation at Week 8 by Investigators</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators assessed the presence/absence and the intensity of regurgitation at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized disappearance of regurgitation were defined as those who had a regurgitation at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggravation of Heartburn at Week 8 by Investigators</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators assessed the presence/absence and the intensity of heartburn at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of heartburn were defined as those who had no heartburn at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggravation of Epigastric Pain at Week 8 by Investigators</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators assessed the presence/absence and the intensity of epigastric pain at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of epigastric pain were defined as those who had no epigastric pain at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggravation of Upper Abdominal Discomfort at Week 8 by Investigators</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators assessed the presence/absence and the intensity of upper abdominal discomfort at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of upper abdominal discomfort were defined as those who had no upper abdominal discomfort at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggravation of Regurgitation at Week 8 by Investigators</measure>
    <time_frame>8 weeks</time_frame>
    <description>The investigators assessed the presence/absence and the intensity of regurgitation at baseline and Week 8 based on questioning the patients or patients' guardians and the patient diary. Patients who recognized aggravation of regurgitation were defined as those who had no regurgitation at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCtau) of Esomeprazole After at Least 5 Days of Repeated Dose</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Esomeprazole After at Least 5 Days of Repeated Dose</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Esomeprazole After at Least 5 Days of Repeated Dose</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of Esomeprazole After at Least 5 Days of Repeated Dose</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life (t1/2) of Esomeprazole After at Least 5 Days of Repeated Dose</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Clearance (CL/F) of Esomeprazole After at Least 5 Days of Repeated Dose</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Esomeprazole After at Least 5 Days of Repeated Dose</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Gastric Ulcer (GU)</condition>
  <condition>Duodenal Ulcer (DU)</condition>
  <condition>Anastomotic Ulcer (AU)</condition>
  <condition>Non-erosive Reflux Esophagitis Disease (NERD)</condition>
  <condition>Reflux Esophagitis (RE)</condition>
  <condition>Zollinger-Ellison Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1: D961H sachet 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age: ≥1 year Weight: &lt;20 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: D961H capsule 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age: ≥1 year to 11years Weight: ≥20 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: D961H capsule 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age: ≥1 year to 11years Weight: ≥20 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: D961H capsule 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age: 12 to 14 years Weight: ≥20 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: D961H capsule 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age: 12 to 14 years Weight: ≥20 kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961H sachet 10 mg</intervention_name>
    <arm_group_label>Group 1: D961H sachet 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961H capsule 10mg</intervention_name>
    <arm_group_label>Group 2: D961H capsule 10mg</arm_group_label>
    <arm_group_label>Group 4: D961H capsule 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961H capsule 20 mg</intervention_name>
    <arm_group_label>Group 3: D961H capsule 20 mg</arm_group_label>
    <arm_group_label>Group 5: D961H capsule 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed written informed consent from the patient's guardian

          -  Patients aged ≥ 1 year to 14 years old

          -  Patients who have a diagnosis of or suspected to have GU, DU, AU, NERD, RE or
             Zollinger-Ellison syndrome.

        Exclusion Criteria:

          -  Patients less than 10 kg in weight.

          -  Use of any other investigational compounds or participations in another clinical trial
             within 4 weeks prior to the randomisation/registration.

          -  Significant clinical illness within 4 weeks prior to the registration

          -  Presence of hepatic diseases or other conditions that could interfere with evaluation
             of the study as judged by the investigators.

          -  Positive for pregnancy test by urinary or lactation for post-menarchal females.

          -  Previous total gastrectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izumi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maebashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saitama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Setagaya-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shimotsuke-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suzaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ureshino-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <results_first_submitted>September 27, 2016</results_first_submitted>
  <results_first_submitted_qc>November 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2017</results_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric ulcer (GU)</keyword>
  <keyword>Duodenal ulcer (DU)</keyword>
  <keyword>Anastomotic ulcer (AU)</keyword>
  <keyword>Non-erosive reflux esophagitis disease (NERD)</keyword>
  <keyword>Reflux esophagitis (RE)</keyword>
  <keyword>Zollinger-Ellison syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
    <mesh_term>Duodenal Ulcer</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
    <mesh_term>Zollinger-Ellison Syndrome</mesh_term>
    <mesh_term>Gastrinoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled on 24 June 2014 Last subject last visit on 04 April 2016. This study was conducted at a total of 20 sites in Japan.</recruitment_details>
      <pre_assignment_details>Out of 55 enrolled subjects, 50 subjects were registered and 5 subjects were not registered. The reason of no registration was 'Did not meet inclusion/exclusion criteria' (5 subjects).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
        </group>
        <group group_id="P5">
          <title>Group 5</title>
          <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
        </group>
        <group group_id="B5">
          <title>Group 5</title>
          <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" spread="2.2"/>
                    <measurement group_id="B2" value="8.9" spread="0.7"/>
                    <measurement group_id="B3" value="8.4" spread="1.8"/>
                    <measurement group_id="B4" value="13.4" spread="0.7"/>
                    <measurement group_id="B5" value="13.1" spread="0.9"/>
                    <measurement group_id="B6" value="9.5" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-7 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-9 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-11 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-14 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disappearance of Heartburn at Week 8 by Patient Diaries</title>
        <description>The disappearance of heartburn was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of heartburn were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had heartburn at pre-dose in patient diary and obtained available diary data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Disappearance of Heartburn at Week 8 by Patient Diaries</title>
          <description>The disappearance of heartburn was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of heartburn were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
          <population>Participants who had heartburn at pre-dose in patient diary and obtained available diary data at Week 8.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disappearance of Epigastric Pain at Week 8 by Patient Diaries</title>
        <description>The disappearance of epigastric pain was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of epigastric pain were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had epigastric pain at pre-dose in patient diary and obtained available diary data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Disappearance of Epigastric Pain at Week 8 by Patient Diaries</title>
          <description>The disappearance of epigastric pain was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of epigastric pain were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
          <population>Participants who had epigastric pain at pre-dose in patient diary and obtained available diary data at Week 8.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disappearance of Upper Abdominal Discomfort at Week 8 by Patient Diaries</title>
        <description>The disappearance of upper abdominal discomfort was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of upper abdominal discomfort were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had upper abdominal discomfort at pre-dose in patient diary and obtained available diary data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Disappearance of Upper Abdominal Discomfort at Week 8 by Patient Diaries</title>
          <description>The disappearance of upper abdominal discomfort was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of upper abdominal discomfort were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
          <population>Participants who had upper abdominal discomfort at pre-dose in patient diary and obtained available diary data at Week 8.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disappearance of Regurgitation at Week 8 by Patient Diaries</title>
        <description>The disappearance of regurgitation was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of regurgitation were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had regurgitation at pre-dose in patient diary and obtained available diary data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Disappearance of Regurgitation at Week 8 by Patient Diaries</title>
          <description>The disappearance of regurgitation was assessed by the intensity of the symptom at Week 8. Patients who recognized disappearance of regurgitation were defined as those who selected &quot;Mild&quot;, &quot;Moderate&quot;, or &quot;Severe&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;None&quot; at Week 8.</description>
          <population>Participants who had regurgitation at pre-dose in patient diary and obtained available diary data at Week 8.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aggravation of Heartburn at Week 8 by Patient Diaries</title>
        <description>The aggravation of heartburn was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of heartburn were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had no heartburn at pre-dose in patient diary and obtained available diary data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Aggravation of Heartburn at Week 8 by Patient Diaries</title>
          <description>The aggravation of heartburn was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of heartburn were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
          <population>Participants who had no heartburn at pre-dose in patient diary and obtained available diary data at Week 8.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aggravation of Epigastric Pain at Week 8 by Patient Diaries</title>
        <description>The aggravation of epigastric pain was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of epigastric pain were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had no epigastric pain at pre-dose in patient diary and obtained available diary data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Aggravation of Epigastric Pain at Week 8 by Patient Diaries</title>
          <description>The aggravation of epigastric pain was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of epigastric pain were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
          <population>Participants who had no epigastric pain at pre-dose in patient diary and obtained available diary data at Week 8.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aggravation of Upper Abdominal Discomfort at Week 8 by Patient Diaries</title>
        <description>The aggravation of upper abdominal discomfort was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of upper abdominal discomfort were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had no upper abdominal discomfort at pre-dose in patient diary and obtained available diary data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Aggravation of Upper Abdominal Discomfort at Week 8 by Patient Diaries</title>
          <description>The aggravation of upper abdominal discomfort was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of upper abdominal discomfort were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
          <population>Participants who had no upper abdominal discomfort at pre-dose in patient diary and obtained available diary data at Week 8.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aggravation of Regurgitation at Week 8 by Patient Diaries</title>
        <description>The aggravation of regurgitation was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of regurgitation were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had no regurgitation at pre-dose in patient diary and obtained available diary data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Aggravation of Regurgitation at Week 8 by Patient Diaries</title>
          <description>The aggravation of regurgitation was assessed by the intensity of the symptom at Week 8. Patients who recognized aggravation of regurgitation were defined as those who selected &quot;None&quot; to the question about the intensity in the patient diary at pre-dose and had the maximum intensity of &quot;Mild&quot;, &quot;Moderate&quot; or &quot;Severe&quot; at Week 8.</description>
          <population>Participants who had no regurgitation at pre-dose in patient diary and obtained available diary data at Week 8.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disappearance of Heartburn at Week 8 by Investigators</title>
        <description>The investigators assessed the presence/absence and the intensity of heartburn at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized disappearance of heartburn were defined as those who had a heartburn at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had a heartburn at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Disappearance of Heartburn at Week 8 by Investigators</title>
          <description>The investigators assessed the presence/absence and the intensity of heartburn at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized disappearance of heartburn were defined as those who had a heartburn at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
          <population>Participants who had a heartburn at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disappearance of Epigastric Pain at Week 8 by Investigators</title>
        <description>The investigators assessed the presence/absence and the intensity of epigastric pain at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized disappearance of epigastric pain were defined as those who had an epigastric pain at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had an epigastric pain at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Disappearance of Epigastric Pain at Week 8 by Investigators</title>
          <description>The investigators assessed the presence/absence and the intensity of epigastric pain at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized disappearance of epigastric pain were defined as those who had an epigastric pain at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
          <population>Participants who had an epigastric pain at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disappearance of Upper Abdominal Discomfort at Week 8 by Investigators</title>
        <description>The investigators assessed the presence/absence and the intensity of upper abdominal discomfort at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized disappearance of upper abdominal discomfort were defined as those who had an upper abdominal discomfort at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had an upper abdominal discomfort at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Disappearance of Upper Abdominal Discomfort at Week 8 by Investigators</title>
          <description>The investigators assessed the presence/absence and the intensity of upper abdominal discomfort at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized disappearance of upper abdominal discomfort were defined as those who had an upper abdominal discomfort at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
          <population>Participants who had an upper abdominal discomfort at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disappearance of Regurgitation at Week 8 by Investigators</title>
        <description>The investigators assessed the presence/absence and the intensity of regurgitation at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized disappearance of regurgitation were defined as those who had a regurgitation at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had a regurgitation at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Disappearance of Regurgitation at Week 8 by Investigators</title>
          <description>The investigators assessed the presence/absence and the intensity of regurgitation at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized disappearance of regurgitation were defined as those who had a regurgitation at pre-dose and did not have the corresponding symptoms at Week 8 judged by investigators.</description>
          <population>Participants who had a regurgitation at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aggravation of Heartburn at Week 8 by Investigators</title>
        <description>The investigators assessed the presence/absence and the intensity of heartburn at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized aggravation of heartburn were defined as those who had no heartburn at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had no heartburn at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Aggravation of Heartburn at Week 8 by Investigators</title>
          <description>The investigators assessed the presence/absence and the intensity of heartburn at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized aggravation of heartburn were defined as those who had no heartburn at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
          <population>Participants who had no heartburn at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aggravation of Epigastric Pain at Week 8 by Investigators</title>
        <description>The investigators assessed the presence/absence and the intensity of epigastric pain at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized aggravation of epigastric pain were defined as those who had no epigastric pain at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had no epigastric pain at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Aggravation of Epigastric Pain at Week 8 by Investigators</title>
          <description>The investigators assessed the presence/absence and the intensity of epigastric pain at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized aggravation of epigastric pain were defined as those who had no epigastric pain at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
          <population>Participants who had no epigastric pain at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aggravation of Upper Abdominal Discomfort at Week 8 by Investigators</title>
        <description>The investigators assessed the presence/absence and the intensity of upper abdominal discomfort at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized aggravation of upper abdominal discomfort were defined as those who had no upper abdominal discomfort at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had no upper abdominal discomfort at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Aggravation of Upper Abdominal Discomfort at Week 8 by Investigators</title>
          <description>The investigators assessed the presence/absence and the intensity of upper abdominal discomfort at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized aggravation of upper abdominal discomfort were defined as those who had no upper abdominal discomfort at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
          <population>Participants who had no upper abdominal discomfort at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aggravation of Regurgitation at Week 8 by Investigators</title>
        <description>The investigators assessed the presence/absence and the intensity of regurgitation at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized aggravation of regurgitation were defined as those who had no regurgitation at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who had no regurgitation at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Aggravation of Regurgitation at Week 8 by Investigators</title>
          <description>The investigators assessed the presence/absence and the intensity of regurgitation at baseline and Week 8 based on questioning the patients or patients’ guardians and the patient diary. Patients who recognized aggravation of regurgitation were defined as those who had no regurgitation at pre-dose and did have any of the corresponding symptoms at Week 8 judged by investigators.</description>
          <population>Participants who had no regurgitation at pre-dose and were evaluated the symptom at Week 8 by investigators.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCtau) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
        <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the pharmacokinetics (PK).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCtau) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
          <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the pharmacokinetics (PK).</population>
          <units>μmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.04" spread="3.05"/>
                    <measurement group_id="O2" value="3.52" spread="2.35"/>
                    <measurement group_id="O3" value="11.05" spread="5.11"/>
                    <measurement group_id="O4" value="2.38" spread="1.74"/>
                    <measurement group_id="O5" value="5.82" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
        <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
          <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
          <units>μmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.53" spread="3.69"/>
                    <measurement group_id="O2" value="3.09" spread="2.34"/>
                    <measurement group_id="O3" value="10.41" spread="4.55"/>
                    <measurement group_id="O4" value="1.99" spread="1.30"/>
                    <measurement group_id="O5" value="5.45" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
        <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
          <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="2.09"/>
                    <measurement group_id="O2" value="2.09" spread="1.53"/>
                    <measurement group_id="O3" value="5.91" spread="2.19"/>
                    <measurement group_id="O4" value="1.09" spread="0.57"/>
                    <measurement group_id="O5" value="3.13" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
        <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
          <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="2.09" lower_limit="1.03" upper_limit="5.92"/>
                    <measurement group_id="O2" value="1.52" spread="1.53" lower_limit="0.92" upper_limit="6.00"/>
                    <measurement group_id="O3" value="1.47" spread="2.19" lower_limit="0.93" upper_limit="1.52"/>
                    <measurement group_id="O4" value="1.57" spread="0.57" lower_limit="0.93" upper_limit="2.95"/>
                    <measurement group_id="O5" value="1.75" spread="1.36" lower_limit="0.95" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-life (t1/2) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
        <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (t1/2) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
          <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.18"/>
                    <measurement group_id="O2" value="0.97" spread="0.55"/>
                    <measurement group_id="O3" value="1.08" spread="0.44"/>
                    <measurement group_id="O4" value="1.37" spread="0.88"/>
                    <measurement group_id="O5" value="1.06" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Clearance (CL/F) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
        <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Clearance (CL/F) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
          <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" spread="1.92"/>
                    <measurement group_id="O2" value="12.44" spread="8.90"/>
                    <measurement group_id="O3" value="6.44" spread="3.37"/>
                    <measurement group_id="O4" value="23.33" spread="24.93"/>
                    <measurement group_id="O5" value="10.94" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
        <time_frame>0, 0.5, 1, 1.5, 2, 3, 4 and 6 hours post-dose after at least 5 days of repeated dose</time_frame>
        <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) of Esomeprazole After at Least 5 Days of Repeated Dose</title>
          <population>All patients who had at least one plasma concentration data after administration of study drug without any protocol deviations that would have an impact on the PK.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" spread="1.24"/>
                    <measurement group_id="O2" value="16.56" spread="16.21"/>
                    <measurement group_id="O3" value="9.21" spread="4.00"/>
                    <measurement group_id="O4" value="44.73" spread="72.03"/>
                    <measurement group_id="O5" value="15.90" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected from the date of signing of informed consent to 8 weeks or withdrawal. Other adverse events were collected from the start of investigational drug administration to 8 weeks or withdrawal.</time_frame>
      <desc>During the administration period, the investigator/clinical research coordinator contacted the patient or patients’ guardian (e.g. by phone) at least once in every week to confirm patient’s health condition and compliance of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>D961H sachet 10 mg Age: 1-11 years and Weight: &lt;20 kg</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>D961H capsule 10 mg Age: 1-11 years and Weight: ≥20 kg</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>D961H capsule 20 mg Age: 1-11 years and Weight: ≥20 kg</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>D961H capsule 10 mg Age: 12-14 years and Weight: ≥20 kg</description>
        </group>
        <group group_id="E5">
          <title>Group 5</title>
          <description>D961H capsule 20 mg Age: 12-14 years and Weight: ≥20 kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mumps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All PIs were prohibited to disclose all information related to this study without AstraZeneca approval before this study was completed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Masahiro Nii</name_or_title>
      <organization>Biometrics Department, Science Affairs Division, R&amp;D, AstraZeneca Japan</organization>
      <email>Masahiro.Nii@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

